14th ICID - Poster Abstracts - International Society for Infectious ...

When citing these abstracts please use the following reference:
Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number.
Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1
is available electronically on http://www.sciencedirect.com
Final Abstract Number: 28.008
Session: Influenza
Date: Wednesday, March 10, 2010
Time: 12:30-13:30
Room: Poster & Exhibition Area/Ground Level
Type: Poster Presentation
Intravenous peramivir for treatment of influenza A and B infection in high-risk patients
S. Kohno 1 , H. Kida 2 , M. Mizuguchi 3 , N. Hirotsu 4 , T. Ishida 5 , J. Kadota 6 , J. Shimada 7
1 Nagasaki University, Nagasaki, Japan, 2 Hokkaido University, Sapporo, Japan, 3 Tokyo University,
Tokyo, Japan, 4 Hirotsu Clinic, Kawasaki, Japan, 5 Kurashiki Central Hospital, Kurashiki, Japan,
6 Oita University, Yufu, Japan, 7 St. Marianna University School of Medicine, Kawasaki, Japan
Background: The ongoing pandemic of 2009/H1N1 influenza has increased the awareness of
the impact and unpredictable nature of influenza. This in turn has raised the interest in the
development of additional drugs to treat the disease when vaccinations fall short. The patient
population of most concern are those classified as "high-risk" where influenza causes substantial
morbidity and mortality. This high-risk group comprises individuals with underlying chronic
disease. In this study, efficacy and safety of intravenous administration of peramivir were
evaluated in influenza patients with one or more high-risk co morbidities.
Methods: The study was a double-blind, multi-center study of intravenous peramivir with dosing
over multiple days. The study enrolled 42 influenza patients with complications due to one or
more qualifying conditions: diagnosis with poorly controlled diabetes mellitus, a chronic
respiratory disease requiring pharmacotherapy, or current treatment with any immunosuppressive
drug. Peramivir was administered at 300 mg or 600 mg per day, and the duration was adjusted
(up to five days) on a case-by-case basis, depending on the patient’s temperature and clinical
condition as determined by the treating physician.
Results: In this study, the median time to alleviation of symptoms in all 37 evaluable patients
treated with either 300 mg or 600 mg peramivir daily was 68.6 hrs (90% CI, 41.5 hrs - 113.4 hrs).
The median time for each group (300 mg and 600 mg) was 114.4 hrs and 42.3 hrs respectively,
while the time for each group categorized as single-dosed (n=10) and multiple-dosed (n=27) was
92.0 hrs and 64.1 hrs, respectively. The incidence of pneumonia, which was the main
complication resulting from influenza was 8.1% (3/37). There were no drug-related SAEs
throughout the study.
Conclusion: The results suggest that intravenous peramivir was effective for treatment of
influenza patients with a high-risk for complications co morbidities and increased risk for
complications due to influenza infection.